title: Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients.
abstract: The efficacy of current hepatitis C therapy in HIV/HCV-coinfected patients is largely dependent on HCV genotype. The annual prevalence of HCV genotypes/subtypes and their influence on HCV clearance with antiviral treatment were examined in a dynamic cohort of HIV/HCV-coinfected patients followed up in Madrid since 2000. Patients entered the cohort at first visit and left the cohort when HCV clearance was achieved with HCV therapy or when follow-up was interrupted for any reason, including death. A total of 672 HIV/HCV-coinfected patients constituted the cohort. The mean follow-up time was 5.5 years, corresponding to 4108 patient-years. Mean age at entry was 37 years, and 73% were men and 86% were intravenous drug users. Overall distribution of HCV genotypes was as follows: 57.1% HCV-1 (1a: 29.2%, 1b: 20.4%, unknown: 7.6%), 1.3% HCV-2, 25.4% HCV-3 and 15.9% HCV-4. A total of 274 (40.8%) patients were treated with peginterferon-ribavirin, of whom 116 (42.3%) achieved HCV clearance following 1-3 courses of therapy. The proportion of HCV-1/4 rose from 71.7% in 2000 to 76.8% in 2008, whereas the proportion of HCV-2/3 fell from 28.1% in 2000 to 23.2% in 2008. The yearly prevalence increased for HCV-1 (R(2) : 0.92, b: 0.59, P < 0.001) and HCV-4 (R(2) : 0.77, b: 0.33, P < 0.005) and conversely diminished for HCV-3 (R(2) : 0.94, b: -0.82, P < 0.001). In summary, the prevalence of HCV-1 and HCV-4 has increased over the last decade in HIV/HCV-coinfected patients, whereas conversely it has declined for HCV-3, in association with the wider use of HCV therapy (41%) in this population.
authors.affiliation: Department of Infectious Diseases & CIBERehd, Hospital Carlos III, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Medrano
authors.forename: S
authors.initials: S
authors.lastname: Resino
authors.forename: E
authors.initials: E
authors.lastname: Vispo
authors.forename: A
authors.initials: A
authors.lastname: Madejón
authors.forename: P
authors.initials: P
authors.lastname: Labarga
authors.forename: P
authors.initials: P
authors.lastname: Tuma
authors.forename: L
authors.initials: L
authors.lastname: Martín-Carbonero
authors.forename: P
authors.initials: P
authors.lastname: Barreiro
authors.forename: S
authors.initials: S
authors.lastname: Rodriguez-Novoa
authors.forename: I
authors.initials: I
authors.lastname: Jiménez-Nacher
authors.forename: V
authors.initials: V
authors.lastname: Soriano
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D004359:Drug Therapy, Combination / Q000639:trends; D005500:Follow-Up Studies; D005838:Genotype; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology*; D006679:HIV Seropositivity; D016174:Hepacivirus / Q000145:classification / Q000187:drug effects / Q000235:genetics*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D015994:Incidence; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D011157:Population Dynamics; D015995:Prevalence; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D012254:Ribavirin / Q000627:therapeutic use; D015819:Substance Abuse, Intravenous
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D012254:Ribavirin; D007372:Interferons